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Background: The DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT) causes resistance of cancer
cells to alkylating agents and, therefore, is a well-established predictive marker for high-grade gliomas that are
routinely treated with alkylating drugs. Since MGMT is highly epigenetically regulated, the MGMT promoter
methylation status is taken as an indicator of MGMT silencing, predicting the outcome of glioma therapy. MGMT
promoter methylation is usually determined by methylation specific PCR (MSP), which is a labor intensive and
error-prone method often used semi-quantitatively. Searching for alternatives, we used closed-tube high resolution
melt (HRM) analysis, which is a quantitative method, and compared it with MSP and pyrosequencing regarding its
predictive value.
Results: We analyzed glioblastoma cell lines with known MGMT activity and formalin-fixed samples from IDH1
wild-type high-grade glioma patients (WHO grade III/IV) treated with radiation and temozolomide by HRM, MSP,
and pyrosequencing. The data were compared as to progression-free survival (PFS) and overall survival (OS) of
patients exhibiting the methylated and unmethylated MGMT status. A promoter methylation cut-off level relevant
for PFS and OS was determined. In a multivariate Cox regression model, methylation of MGMT promoter of
high-grade gliomas analyzed by HRM, but not MSP, was found to be an independent predictive marker for OS.
Univariate Kaplan–Meier analyses revealed for PFS and OS a significant and better discrimination between
methylated and unmethylated tumors when quantitative HRM was used instead of MSP.
Conclusions: Compared to MSP and pyrosequencing, the HRM method is simple, cost effective, highly accurate
and fast. HRM is at least equivalent to pyrosequencing in quantifying the methylation level. It is superior in
predicting PFS and OS of high-grade glioma patients compared to MSP and, therefore, can be recommended
being used routinely for determination of the MGMT status of gliomas.
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Patients suffering from high-grade gliomas (notably glio-
blastoma multiforme, WHO grade IV) have a dismal
prognosis (14.6 months median survival and a 2-year
survival rate of 26 %) [1]. Their first-line therapy is based
on the DNA alkylating agent temozolomide (Temodal®)
and ionizing radiation [1, 2]. Temozolomide exerts its
cytotoxic effect by the induction of O6-methylguanine,
which represents an apoptosis-inducing DNA damage
[3]. As second line drugs, DNA-chloroethylating agents
(lomustine, nimustine, carmustine, and fotemustine) are
being used, which cause toxicity via the formation of
O6-chloroethylguanin and subsequently formed DNA in-
terstrand crosslinks. In some studies, lomustine was
used in combination with temozolomide in glioblastoma
therapy [4–6]. The key node in defense against the cyto-
toxic DNA lesion O6-alkylguanine is O6-methylguanine-
DNA methyltransferase (MGMT), a suicide repair en-
zyme that reverts the damage in a fast, stoichiometric,
and error-free reaction [3, 7]. The expression of the re-
pair protein and its suicide repair activity is inversely re-
lated to the killing response of glioblastoma cells in vitro
[8] and the therapeutic outcome of glioblastoma therapy
[9]. Thus, MGMT is an important predictive marker for
high-grade gliomas [10, 11].
Since the determination of the MGMT activity relies
usually on a radioactive assay, alternative techniques for
detecting the MGMT status were established. These
methods are based on the finding that the MGMT ex-
pression is highly regulated by MGMT promoter methy-
lation [12, 13]. Most studies focused on methylation of
two CpG islands positioned between −328 and −182 and
between +28 and +117 relative to the ATG of the
MGMT gene, which have been shown to provoke tran-
scriptional silencing [14, 15]. Methylation of individual
CpG sites in these islands of the MGMT promoter was
shown to correlate with loss of MGMT protein expres-
sion in the tumor tissue [16]. MGMT promoter methyla-
tion is frequently analyzed via methylation specific PCR
(MSP) [17] for which primer pairs flanking different
CpG sites within the MGMT promoter are being used.
The most commonly used primer was described by the
Esteller group [18], which was used in a large number of
studies. These studies revealed epigenetic silencing of
MGMT in about 45 % of the cases and established a cor-
relation between MGMT promoter methylation and pa-
tient’s overall survival (OS) and progression-free survival
(PFS) [11, 16, 18–20].
MSP is a labor-intensive method that is often used in
a non-quantitative way. It is error-prone as it requires
the removal of the PCR product from the tube for fur-
ther analysis, creating the potential for contamination.
Searching for alternatives to MSP, we used a quantitative
closed-tube real-time PCR with high resolution melt(HRM) analysis [21]. Using this method, we analyzed
tumor specimens obtained from high-grade glioma pa-
tients and compared the data with MSP and also with
pyrosequencing (PSQ). The data obtained were then re-
lated to progression-free survival (PFS) and overall sur-
vival (OS) of the patients. We found that HRM is clearly
superior to MSP in discriminating between responders
and non-responders. HRM was equal to PSQ, which is,
however, more difficult to perform than HRM. We con-
clude that HRM is a fast, robust, and reliable method and
excellent in predicting the outcome of glioma therapy.
Methods
Patients and treatments
Paraffin-embedded tumor samples were studied from 83
high-grade (WHO grade III and IV) glioma patients
treated at the Neurosurgical Center at the University
Medical Center of Mainz, Germany. Tumor specimens
were obtained before radio-chemotherapy, formalin
fixed, and paraffin embedded. DNA was extracted ac-
cording to standard protocols. All patients provided
written informed consent. The study was approved by
the institutional ethics committee of the University
Medical Center Mainz. Therapy regimen: All patients re-
ceived combined radio-chemotherapy with temozolo-
mide according to the EORTC regimen [1, 2]. In case of
tumor progression, second-line therapy was adminis-
tered, e.g., dose-dense temozolomide, CCNU, or bevaci-
zumab. Two patients were lost to the follow-up after the
first progress. The investigator performing the biochem-
ical assays was blinded for all clinical information.
Cell culture
Cells were cultured in DMEM (Gibco) supplemented
with 10 % fetal calf serum (Gibco) and grown at 37 °C,
5 % CO2 atmosphere. DNA was isolated using phenol-
chloroform followed by ethanol precipitation. The DNA
samples were stored at −80 °C.
DNA standards
Buccal DNA from a healthy donor was used to generate
DNA standards. Fifty nanograms of DNA was used for
whole genome amplification using the REPLI-g midi kit
(Qiagen) to generate the unmethylated standard DNA.
The reaction was performed according to the manufac-
turer’s instructions. An aliquot of 100 μg was in vitro
methylated with 400 U SssI methylase and 640 μM SAM
(NEB) according to the manufacturer’s instructions.
After 4 h at 37 °C, additional SAM and 50 U of SssI
methylase were added and incubated overnight at 37 °C
to ensure complete methylation. Both methylated and
unmethylated standard DNA were purified by phenol-
chloroform extraction followed by ethanol precipitation,
suspended in DNase-free water and stored at −80 °C.
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Five hundred nanograms of DNA underwent bisulfite
treatment using the EZ DNA methylation-kit (ZymoRe-
search) according to the manufacturer’s protocol to
convert all unmethylated cytosine to uracil while leaving
5-methylcytosine unaltered, and was then eluted in 25 μl
of DNase-free water. DNA methylation of the MGMT
promoter was analyzed by MSP, pyrosequencing (PSQ),
and HRM. The analyzed promoter sequences are shown
in Fig. 1a.Analysis of the MGMT promoter methylation by MSP
For MSP of the MGMT promoter, we used primers pre-
viously described [18]. The method was carried out as
described previously [22]. Classification was carried out
binary, MGMT unmethylated and MGMT methylated,
respectively.a
b
Fig. 1 HRM analysis in glioma cell lines. a MGMT promoter methylation wa
analyzed by each of the assays are shown. b MGMT promoter methylation
corresponding MSP categorization (m methylated; u unmethylated). Ordina
between MGMT suicide-enzyme activity and level of promoter methylation
correlation between MGMT promoter methylation and MGMT activity wasAnalysis of the MGMT promoter methylation by high
resolution melt (HRM) curve analysis
A search for CpG islands in the MGMT promoter was per-
formed using the Geneious 6 software (Biomatters). For the
HRM of the MGMT promoter, we used methylation inde-
pendent primers (r4 fwd: 5′-GGATATGTTGGGATAGTT-
3′ and r4 rev: 5′-CCCAAACACTCACCAAAT-3′) without
a CpG site in it to avoid biased amplification (Additional
file 1: Table S1). Primers were designed using the Pyromark
assay Designer 2.0 (Qiagen). Region r2 and r4 include the
binding sites of the MSP primers published by Esteller et al.
[16]. PCR amplification and HRM analyses were performed
using a CFX96 real-time PCR system (BioRad). Each PCR
was performed in a final volume of 15 μl, containing 7.5 μl
precision melt supermix (BioRad), 400 nM of each primer,
and 20 ng of bisulfite-converted DNA (theoretical concen-
tration presuming no loss of DNA during bisulfite modifi-
cation). PCR amplification was performed with one step ofc
s analyzed by HRM, MSP, and PSQ. The regions in the MGMT promoter
of 14 GBM cell lines measured by HRM (in triplicates) and the
te shows the methylation level determined by HRM. c Relationship
determined by HRM using the r4 primer in 14 GBM cell lines. A
found (r = −0.69; p < 0.01)
Switzeny et al. Clinical Epigenetics  (2016) 8:49 Page 4 of 1095 °C for 2 min, 45 cycles of 95 °C for 10 s, 54 °C for 30 s,
and 72 °C for 15 s; followed by an HRM step of 95 °C for
30 s, 60 °C for 1 min, 70 °C for 10 s, and continuous acqui-
sition to 90 °C at one acquisition per 0.2 °C. For cell lines,
each reaction was performed in technical duplicates of bio-
logical triplicates, and in technical duplicates for the pa-
tient’s samples. Fully methylated and unmethylated
bisulfite-converted DNA was mixed to obtain the following
ratios of methylation: 2.1, 24.3, 46.4, 68.6, and 90.8 % (the-
oretically 0, 25, 50, 75, and 100 %) and were included in du-
plicates in each assay, as well as a non-template control and
a genomic DNA control. Commercially available bisulfite-
converted DNA standards (Qiagen) were analyzed together
with our internal DNA standards. HRM data was analyzed
using Bio-Rad Precision Melt Analysis software (BioRad),
with output plots produced as normalized melting
curves (Additional file 1: Figure S1A). Normalized
relative fluorescence units (RFUs) were exported to
Prism 6 (Graphpad). Area under the curve (AUC)
was calculated, and the linear regression was used to
interpolate the unknown samples from the standards.
R2 was >0.98 (Additional file 1: Figure S1B).
Analysis of the MGMT promoter methylation by
pyrosequencing
The DNA methylation standards and patients DNA were
analyzed by PSQ (Additional file 1: Figure S1C) to quan-
tify their methylation content. PCR was performed using
the PyroMark Q96 CpG MGMT kit (Qiagen) according
to manufacturer’s instructions. The samples were then
processed in the PyroMark Q96 ID instrument (Qiagen),
and the obtained data were analyzed by PyroMark CpG
Software. Patients were dichotomized upon a mean
methylation level threshold of 8 % according to previous
studies [23–25]. To further validate the methylation
values of the HRM assay, we performed pyrosequencing
for the whole HRM amplicon on a Pyromark Q24 ad-
vanced (Qiagen) for 38 patient samples and the DNA
standards. The forward primer was also used as a se-
quencing primer (Additional file 1: Figure S2A and Table
S1). The 38 methylation scores determined by HRM and
pyrosequencing showed a high correlation (r = 0.926, p <
0.0001, Additional file 1: Figure S2B). The unmethylated
DNA standard was methylated to an extent of 2.1 %,
and the methylated DNA standard showed 90.8 % mean
methylation at the MGMT promoter region. These
values were taken for the linear regression analysis of
data obtained by HRM (see above).
MGMT activity assay
MGMT activity was measured for 14 GBM cell lines in
triplicates using a protocol that has been published pre-
viously [26]. Briefly, the method is a radioactive assay in
which tritium-labeled methyl group from the O6-position of guanine is transferred to the protein in the
cell extract. Data were expressed as fmol of radioactivity
transferred from 3H-labelled DNA to protein per milli-
gram of protein within the sample.
IDH1 mutation detection
The IDH1 mutational status was determined by immu-
nohistochemistry using an anti-IDH1 R132H antibody
(Dianova). We further validated the results by pyrose-
quencing (Additional file 1: Figure S1D) in all samples
using primers published previously on the Pyromark
Q96 ID instrument [27]. We excluded all IDH1-mutated
patient samples from further analysis.
Statistical analysis
Univariate survival and progression analyses and survival
curves were estimated by the Kaplan–Meier method and
compared using the log-rank test. Multivariate survival
and progression analyses were performed using multiple
Cox regression analysis. Two-tailed Spearman–Rho test
was used to determine bivariate correlations between
methylation status and patient characteristics. Two-
tailed Pearson’s test was used to determine correlations
of continuous methylation scores of the HRM and pyro-
sequencing assay. A p value <0.05 was considered statis-
tically significant. An ROC curve was generated to graph
the sensitivity and specificity of MSP, PSQ, and HRM
status to predict OS ≥ 18 months and PFS ≥ 12 months.
All statistics were computed using SPSS 23 (IBM) and
plotted with Prism 6 (Graphpad).
Results
The human MGMT gene was reported to harbor a CpG
island of 762 bp in the promoter region (−531 to +231
from the ATG) containing 98 CpG sites [28]. We per-
formed initially an in silico search for CpG islands 8 kb
upstream and 1 kb downstream of the MGMT coding
sequence that could be useful for HRM. Using Geneious
software, we found a CpG island −729 to +461 from
ATG, largely confirming the above study. Four primer
sets (Additional file 1: Table S1) were analyzed as to
their suitability for methylation analysis by HRM, using
MGMT proficient (HaCaT) and MGMT deficient
(LN229) cells. Primer pair r1 generated a 392 bp ampli-
con producing several melt peaks. It was therefore
unsuitable for HRM analysis. Using primer pair r2 (cov-
ering the MSP reverse primer binding site), we observed
only small differences in the methylation level between
MGMT proficient versus deficient cells. The primer
pairs r3 and r4 revealed extensive differences in the
MGMT promoter methylation level and, therefore, were
suitable for further analysis. The MGMT promoter
methylation status was determined quantitatively by
HRM in 14 GBM cell lines and compared with MSP
Table 2 Characteristics of patients and their MGMT promoter
methylation status determined by HRM, MSP, and PSQ in 65
IDH1 wt malignant gliomas
Characteristics n HRM me (%) MSP me (%) PSQ me (%)
All patients 65 41.5 30.8 46.2
Woman 22 40.9 31.8 40.9
Man 43 41.9 30.2 48.8
Age ≥70 27 44.4 25.9 44.4
Age <70 38 39.5 34.2 47.4
Grade III 7 42.9 42.9 42.9
Grade IV 58 41.4 29.3 46.6
Table 1 Characteristics of patients and their MGMT promoter methylation status determined by HRM, MSP, and PSQ in 83
malignant gliomas, including 18 IDH1-mutated cases
Characteristics n HRM me (%) MSP me (%) PSQ me (%) IDH1 mut (%)
All patients 83 51.8 37.3 54.2 21.7
Woman 28 50.0 39.3 53.6 21.4
Man 55 52.7 36.4 54.5 21.8
Age ≥70 27 44.4 25.9 44.4 0.0
Age <70 56 55.4 42.9 58.9 32.1
Grade III 23 73.9 56.5 69.6 69.6
Grade IV 60 43.3 30.0 48.3 3.3
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tion determined by HRM and MGMT activity shows
that the MGMT activity declines with increasing MGMT
promoter methylation level, with r4 showing the best in-
verse correlation (Fig. 1c for r4, and Additional file 1:
Figure S1E for r3). Therefore, primer pair r4 covering 12
CpGs, including the region that was analyzed using the
MSP and PSQ assay (Fig. 1a), was used for our further
studies with tumor tissue.
MGMT promoter methylation was analyzed in paraffi-
nized tumor samples from 83 glioma patients. We found
that MGMT promoter methylation was not associated
with the patient’s age and sex (Table 1). MGMT promoter
methylation was detected by MSP in 37.3 % of the cases,
whereas HRM showed promoter methylation in 51.8 %
and PSQ in 54.2 % of the samples (Table 1). Thus, HRM
was similar to PSQ in detecting promoter methylation.
Since IDH1-mutated tumors show a favorable patient
survival and since the IDH1 status is considered to be an
independent prognostic marker for WHO grade III gliomas
[29], we decided to exclude IDH1-mutated samples from
further analysis. IDH1 mutation was analyzed by immuno-
histochemistry using an anti-IDH1 R132H antibody and
further confirmed by sequencing. The analysis revealed 18
of 83 analyzed tumors as IDH1 mutated. The IDH1 muta-
tions were predominantly observed in grade III (88.9 %),
but also in grade IV tumors (11.1 %) and a high correlation
with MGMT promoter methylation was observed. Thus,
88.9 % of IDH1-mutated tumors displayed MGMT pro-
moter methylation (Additional file 1: Table S2), confirming
data in the literature [30, 31].
To determine an optimal cut-off value for discriminating
between methylated and unmethylated MGMT promoter,
ROC curves were plotted for 15 methylation cut-off scores
(1–15 %) to identify the optimum cut-off level for the pre-
diction of PFS ≥12 months and OS ≥18 months. The cut-
off value of 5 % showed the largest AUC for both PFS
(0.705) and OS (0.637) (Additional file 1: Table S3) confirm-
ing the suitability of a 5 % cut-off value for discriminating
between the methylated and the unmethylated MGMT
promoter.The association between MGMT promoter methyla-
tion and clinical outcome (using a 5 % cut-off value)
comparing HRM, MSP, and PSQ was analyzed in tumor
material of 65 IDH1 wt glioma patients (seven gliomas
grade III and 58 grade IV). The data are shown in
Additional file 1: Table S2 for all patients in the study
(including IDH1 mutated) and in Table 2 for IDH1 wild-
type tumors only. In Table 2, we also compiled the per-
centage of MGMT-methylated tumors upon sex, age,
and tumor grade, indicating no differences to exist be-
tween these groups. Overall, the HRM values were again
more similar to PSQ than to MSP values. A comparison
of Kaplan–Meier estimates of PFS using the method of
HRM, MSP, and PSQ is shown in Fig. 2, panels a, b, and
c, respectively. For HRM and PSQ, the difference in PFS
was significant, whereas MSP did not show a significant
difference. Kaplan–Meier estimates of OS of patients
using the methods of HRM, MSP, and PSQ are shown in
Fig. 2, panels d, e, and f, respectively (an overlay of all
Kaplan–Meier curves is shown in Additional file 1: Figure
S3). The data for OS also revealed an enhanced predictive
value when HRM or PSQ was used compared to MSP. In
a bivariate analysis, the methylation status of the MGMT
promoter was correlated with PFS (r = 0.252, p = 0.042)
and Karnofsky score (r = 0.336, p = 0.007). In contrast,
data obtained by MSP and PSQ failed to generate signifi-




Fig. 2 Kaplan–Meier estimates of PFS and OS according to MGMT promoter methylation status determined by HRM, MSP, and PSQ. Kaplan–Meier
estimates for PFS and OS of 65 high-grade glioma patients. PFS of patients with unmethylated and methylated MGMT status, determined by HRM (a),
MSP (b), and PSQ (c). OS of patients with unmethylated and methylated MGMT status, determined by HRM (d), MSP (e), and PSQ (f). Significance levels
were determined by the log-rank test. U unmethylated; M methylated MGMT promoter
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methylation were further compared by ROC analysis.
ROC curves were generated to depict the sensitivity and
specificity of MGMT promoter methylation status deter-
mined by HRM, MSP, PSQ as well as age <70 to predict
PFS ≥12 months and OS ≥18 months. The AUC was
clearly larger for HRM than for MSP both for PFS
(Fig. 3a) and OS (Fig. 3b), supporting the notion thatdichotomization of patients by HRM leads to less false
positive and false negative results compared to MSP in
predicting survival. The AUC for HRM and PSQ is
nearly the same, indicating both methods provide the
same discrimination accuracy.
Furthermore, univariate and multivariate Cox regres-
sion analyses were performed with the factors HRM,








Age < 70: 0.601
a b
Fig. 3 ROC curves for MGMT promoter methylation. Receiver operator characteristics (ROC) curve calculated on the basis of MGMT
promoter methylation determined by MSP (orange line), HRM (blue line), PSQ (violet line), and age <70 (green line). ROC curves were
calculated for (a) PFS ≥12 months and (b) OS ≥18 months. The area under the curve (AUC) corresponds to the prediction of survival,
with a value of 1 indicating perfect discrimination, and a value of 0.5 no better than chance discrimination
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was found to be the only significant independent prognos-
tic factor for OS (HR 0.473, 95 % CI 0.231–0.969, p =
0.041) (Table 3). Overall, the study shows that for both PFS
and OS, HRM was clearly superior to MSP in discriminat-
ing between responders and non-responders and equally
effective than PSQ (data are summarized in Table 4).
Discussion
The therapy of high-grade gliomas is based on drugs that
alkylate the DNA in the O6-position of guanine such as
temozolomide and the nitrosoureas lomustine, nimustine,
and carmustine. For these drugs, MGMT is a key node in
the repair of the principal toxic lesion O6-alkylguanine [3],
determining the level of drug resistance and being a de-
cisive factor in identifying responders and non-responders
[10, 11]. The determination of MGMT activity requires
native tissue and immunohistochemistry suffers from
technical limitations and inter-observer differences [32].
Therefore, the method of choice for determination of the
MGMT status is analysis of the MGMT promoter methy-
lation. Since pyrosequencing is cost-intensive, MGMT
promoter methylation is usually determined by MSP inTable 3 Associations between MGMT promoter methylation status,
and PFS and OS, assessed by univariate (log-rank test) and multivaria
PFS
Univariate (p) Multivariate (HR, 95%
MSP me 0.718 1.456, 0.730–2.903, 0.2
PSQ me 0.030 0.729, 0.358–1.482, 0.3
HRM me 0.013 0.539, 0.278–1.045, 0.0
Sex = woman 0.742 0.958, 0.545–1.684, 0.8
Age <70 0.106 0.677, 0.389–1.178, 0.1the clinical routine. The human MGMT promoter is com-
plex, harboring more than 90 CpG sites that are subject to
cytosine methylation [28, 33]. For MSP, only a few of these
sites in the MGMT promoter are being used. Although
the methylation of the CpG sites appear to be highly vari-
able in tumors, methylation of these target sites corre-
sponds well with the therapeutic response, indicating that
some CpG sites have a strong impact on epigenetic silen-
cing of MGMT [33]. Of note, >50 CpG sites in the pro-
moter region of MGMT silenced tumors were found
homogeneously methylated [34]. The region commonly
investigated by MSP was reported to show a concordance
of about 85 % with the MGMT mRNA expression [34].
Although, the region encompassing the most often used
MSP primers shows a strong concordance with MGMTsi-
lencing compared to other areas in the promoter [28],
data obtained in different laboratories on this subject are
quite heterogeneous [32–36]. Also for MGMT activity, a
correlation was found between MGMT promoter methy-
lation determined by MSP, but also exceptions do exist
[37] indicating the importance of other methylation sites
(and/or other regulatory mechanisms) in determining the
MGMT expression status. It is obvious that a methoddemographic features, and grade of 65 IDH1 wt glioma patients
te (Cox-regression) analyses
OS
CI, p) Univariate (p) Multivariate (HR, 95% CI, p)
85 0.345 1.270, 0.606–2.661, 0.527
82 0.031 0.762, 0.376–1.544, 0.450
67 0.006 0.473, 0.231–0.969, 0.041
81 0.578 0.918, 0.494–1.705, 0.786
68 0.114 0.590, 0.331–1.052, 0.074
Table 4 MGMT promoter methylation status and progress and survival of patients. Promoter methylation was determined by HRM,
MSP, and PSQ
Promoter status HRM MSP PSQ
Methylated MGMT promoter
Progression-free survival
Median duration (months) 6.0 (3.64–8.36) 4.4 (3.09–5.72) 4.6 (2.88–6.32)
Rate at 6 months (%) 51.9 40.0 46.7
Overall survival
Median duration (months) 14.0 (6.50–21.50) 11.0 (8.19–13.81) 11.0 (0.27–21.74)
Rate at 18 months (%) 48.1 40.0 46.7
Unmethylated MGMT promoter
Progression-free survival
Median duration (months) 4.0 (3.80–4.20) 4.2 (3.67–4.73) 4.0 (3.67–4.33)
Rate at 6 months (%) 31.6 40.0 34.3
Overall survival
Median duration (months) 10.0 (5.03–14.97) 12.0 (7.36–16.64) 11.0 (7.62–14.38)
Rate at 18 months (%) 23.7 31.1 22.9
Numbers in parentheses are 95 % confidence intervals
Switzeny et al. Clinical Epigenetics  (2016) 8:49 Page 8 of 10covering a larger area in the MGMT promoter than
encompassed by the routinely applied MSP is desirable.
Another problem associated with MSP is the quality of
the amplification product, which may arise due to ineffi-
cient PCR [37, 38]. Further limitations in MGMT status
determination are the heterogeneity of the tumor and
contamination of the tumor sample with normal cells.
This pertains, however, to any PCR-based method.
HRM is an alternative method for the discrimination be-
tween 5-methylcytosine containing and non-containing
DNA sequences, based on the difference in the melting
curves between methylated and unmethylated templates.
Compared to MSP, the HRM method relies on methyla-
tion standards that are analyzed with unknown samples,
making the method investigator independent. Further-
more, HRM is a closed-tube technique that is less expen-
sive, faster, and less laborious then methods based on
DNA sequencing, including PSQ. The results obtained are
quantitative. As HRM represents a real-time PCR-based
method, quality control is ensured by the amplification
and melting plot. The application of HRM for MGMT
promoter methylation assessment has previously been
proposed [21, 39]; however, a systematic comparison using
a defined cut-off threshold was not undertaken and DNA
standards were not verified by other methods.
To elucidate whether HRM is a feasible and reason-
able alternative to MSP in determining the MGMT pro-
moter methylation status and predicting the high-grade
glioma therapy response, we compared HRM and MSP
systematically. In this study, we included also PSQ,
which is regarded as the “gold standard” for methylation
analysis [40]. First, we showed that HRM correlates with
the MGMT activity in glioblastoma cell lines. Then, wedemonstrated that 51.8, 37.3, and 54.2 % of high-grade
gliomas in our collection (including IDH1-mutated tu-
mors) were promoter methylated as determined by
HRM, MSP, and PSQ, respectively, indicating HRM and
PSQ provided comparable results. Finally, we compared
the patient’s response with the tumor methylation status,
using Kaplan–Meier estimates. The data revealed a signifi-
cant difference in PFS and OS between the methylated
and unmethylated MGMT promoter when HRM and
PSQ was used, while for MSP no significant difference
was found (Fig. 2). This indicates that HRM is superior to
MSP and equal to PSQ in predicting PFS and OS of high-
grade glioma patients. Additional statistical evaluation like
a Cox regression model showed that HRM was the only
significant independent prognostic factor for OS (HR
0.473, 95 % CI 0.231–0.969, p = 0.041), and ROC analysis
revealed that HRM and PSQ led to less false positive and
false negative grouping compared to MSP in predicting
survival. Overall, for both PFS and OS, HRM was clearly
superior to MSP in discriminating between responders
and non-responders and equally effective to PSQ.Conclusions
This is, to our best knowledge, the first study that com-
pares in a well-defined tumor collection HRM, MSP, and
PSQ, defining a distinct HRM promoter methylation
cut-off level relevant for prediction of tumor progression
and patient survival. Since the MGMT promoter methy-
lation status analyzed by HRM is most precise in deter-
mining the patient’s outcome, we recommend HRM as a
feasible and reliable method for routine diagnostics of
high-grade glioma patients.
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Additional file 1: Figure S1. (A) Normalized melt curves in duplicates
showing the melt behavior of methylation standards (red=0 %, pink=25 %,
blue=50 %, green=75 %, orange=100 %) and an unknown sample (black). (B)
Regression model used for MGMT promoter methylation quantification. Area
under the curve (AUC) from the normalized melt curves are used and
regressed to the known methylation level of the standards. The linear
regression model was chosen for quantification (R² > 0.98). (C) Pyrogram of
the MGMT promoter of a patient tumor sample with a mean methylation of
31.4 %. (D) Typical pyrogram obtained from a grade III patient tumor sample
indicating a heterozygous G-to-A point mutation of the IDH1 gene resulting
in a mutation at codon 132 (R132H). (E) Relationship between MGMT protein
activity and promoter methylation (r3) in 14 GBM cell lines. Figure S2.
(A) Pyrogram of the whole HRM (R4) assay region from a patient sample.
(B) Dot-plot of the methylation values obtained in a subsample by HRM and
pyrosequencing showing a high correlation of this two methods. The dotted
line indicates the 95 % CI. Figure S3. Overlay of Kaplan-Meier estimates of
PFS and OS according to MGMT promoter methylation status. Kaplan-Meier
estimates for (A) PFS and (B) OS of 65 high-grade glioma patients
determined by HRM (red lines), MSP (blue) and PSQ (green). The solid and
the dashed lines indicate the group as being categorized unmethylated (UM)
or methylated (ME), respectively. Table S1. Primers used for HRM and
pyrosequencing. Table S2. MGMT promoter methylation status determined
by HRM, MSP, and PSQ in dependence of the IDH1 status. Table S3. ROC
curves were plotted for 15 methylation cut-off scores (1-15 %) for predicting
PFS ≥ 12 months and OS ≥ 18 months. (PPTX 312 kb)Abbreviations
AUC: area under the curve; CCNU: chlorethyl-cyclohexyl-nitroso-urea;
DMEM: Dulbecco’s modified Eagle medium; DNA: deoxyribonucleic acid;
GBM: glioblastoma multiforme; HRM: high resolution melt; IDH1: isocitrate
dehydrogenase 1; MGMT: O6-alkylguanine DNA alkyltransferase;
mRNA: messenger ribonucleic acid; MSP: methylation-specific PCR;
OS: overall survival; PCR: polymerase chain reaction; PFS: progression-free
survival; PSQ: pyrosequencing; RFU: relative fluorescence units; ROC: receiver
operating characteristic; SAM: S-Adenosylmethionin; TMZ: temozolomide.
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